RxDoctor Payments Data

Ernesto Uy, MD

Internal Medicine · Lakeland, FLNPI 1932171030

Payments from drug & device makers

$3,999in general payments, 2019–2025

Across 188 payments — averaging $21.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$764
  • Novartis$596
  • Pfizer$536
  • Abbott$269
  • AstraZeneca$243
  • plus $518 from 9 others

What the payments were for

  • Food & beverage$3,93598%
  • Education$652%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,999 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$229,993
Medicare patients
863
Services billed
2,800

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin270$327,032
OzempicSemaglutide231$324,294
EliquisApixaban312$305,185
FarxigaDapagliflozin Propanediol145$142,205
RybelsusSemaglutide52$101,720
JanuviaSitagliptin Phosphate59$81,095
Repatha SureclickEvolocumab54$57,715
TrulicityDulaglutide26$53,729
XareltoRivaroxaban44$49,513
VascepaIcosapent Ethyl68$36,644
MounjaroTirzepatide22$30,360
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog23$25,415
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$23,084
TradjentaLinagliptin12$17,956
ArexvyRsvpref3 Antigen/As01e/Pf48$14,562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$764$426,015283 claims
PfizerEliquis$536$305,185312 claims
AstraZenecaFarxiga, Symbicort$243$147,678161 claims
GSKArexvy, Shingrix, Trelegy Ellipta, Breo Ellipta$70$38,490120 claims
AbbVieSynthroid$1,073$8,38296 claims
Sumitomo Pharma America, Inc.Gemtesa$46$7,48616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Lakeland

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →